Alnylam Pharmaceuticals built its reputation on a single, elegant idea: if you can quiet a disease-causing gene with a small interfering RNA delivered to the liver, you can treat the disorder at its source. That logic produced approved RNA interference (RNAi) medicines for rare metabolic and amyloid conditions. A trial that updated on the U.S. registry this week shows the company reaching for something harder — using the same gene-silencing chemistry not to fix a metabolic defect in the liver, but to attack a tumor growing in it.
The study, registered as NCT06600321, is titled A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma. It is sponsored by Alnylam, is currently recruiting, and is designed to enroll 158 participants. The first part of the trial is a classic dose escalation; the second is a dose expansion. Crucially, the protocol is explicit that the early work is about finding a usable dose, not proving the drug shrinks tumors.
"The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab."— ClinicalTrials.gov, source
That sequencing matters for anyone reading the record honestly. The primary outcome measures listed are the frequency and severity of adverse events and the occurrence of dose-limiting toxicities during escalation. Antitumor activity is reserved for the expansion phase. In other words, a positive result here is a tolerable dose and a clean enough safety profile to justify expansion — not a survival signal. Readers who see an RNAi drug paired with a checkpoint inhibitor in liver cancer and assume a near-term efficacy readout are getting ahead of the document.
Why the liver makes this combination plausible
The reason an RNAi company can even attempt oncology in this organ is anatomical. The liver is the tissue RNAi therapeutics reach most reliably; hepatocytes take up the conjugated small-RNA payloads efficiently, which is exactly why Alnylam's earlier medicines targeted hepatic genes. A tumor sitting in the same organ is, at least in principle, within delivery range of a platform that has spent fifteen years learning to silence liver genes. The trial name signals the molecular target through its code — BCAT — and pairs the silencer with pembrolizumab, an approved anti-PD-1 antibody, on the well-worn hypothesis that disabling a tumor-intrinsic driver can make the cancer more visible to an immune system that a checkpoint inhibitor has unleashed.
The combination design is doing real work in the protocol. ALN-BCAT is being characterized both as a single agent and layered onto pembrolizumab, and a recommended dose for expansion is sought for each setting separately. That is a deliberate, conservative architecture: it lets investigators learn whether the RNAi agent has standalone tolerability before attributing any later combination toxicity — or benefit — to the partnership. The non-randomized, open-label, parallel structure is standard for a first dose-finding effort, where masking would add little and where every participant has advanced or metastatic disease.
There is also a delivery question lurking beneath the biology. RNAi therapeutics succeed or fail on whether the silencing payload actually reaches the cells it is meant to act on, in enough copies, for long enough. In a metabolic disease the target hepatocytes are healthy, uniform, and abundant; in a tumor the cellular environment is disorganized, the vasculature is abnormal, and uptake can be uneven across the mass. That is one reason a dose-finding study here is not a formality — the recommended expansion dose has to clear not just a toxicity threshold but a pharmacologic one, delivering enough silencing to matter where the cancer cells actually are. The 158-participant enrollment, large for a Phase 1, gives the trial room to interrogate both the monotherapy and combination arms across multiple dose levels before committing to expansion, which is exactly the kind of headroom a novel-target oncology program needs.
What the record does and does not establish
It is worth being precise about the patient population. The listed conditions are advanced hepatocellular carcinoma and metastatic hepatocellular carcinoma — a setting where standard options are limited and where checkpoint-inhibitor regimens already form part of the front-line landscape. A novel mechanism layered onto that backbone is the kind of early-phase swing that defines the riskiest, most interesting tier of oncology development. The trial's recruiting status and December 2024 start date place it squarely in the active first-in-disease window for this asset.
For the patent-and-platform reader, the strategic signal is larger than any single endpoint. RNAi has, until recently, been a chronic-disease modality: dose a stable gene defect, manage a lifelong condition. Pointing it at a solid tumor reframes the platform's addressable map and, by extension, the value of the underlying delivery and sequence chemistry. Whether that reframing holds depends entirely on data this study has not yet produced. The honest read of NCT06600321 today is narrow but real: a credentialed RNAi developer is testing whether its liver-tropic silencing technology can be turned on a liver cancer, and it is doing so with the caution of a protocol that asks first about safety and dose, and only later about whether the tumors respond.
That is the discipline the registry record enforces. The outcome measures are tolerability and dose-limiting toxicity; the expansion-phase efficacy questions are flagged as purpose, not result. Anyone tracking this asset should watch for the recommended expansion doses and the safety profile to emerge first — those are the gates the trial is built to open — before any conversation about activity in advanced liver cancer becomes grounded in evidence rather than mechanism.